Charles Homcy

Fondateur chez BRIDGEBIO PHARMA, INC. Fortune : 31 M $ au 30/06/2024

Profil

Charles J.
Homcy founded Portola Pharmaceuticals LLC in 2003, where he worked as Co-Chairman, President & Chief Executive Officer, Global Blood Therapeutics, Inc. in 2011, where he worked as Independent Director from 2012 to 2019, and BridgeBio Pharma, Inc. in 2015, where he is working as Lead Director & Chairman-Pharmaceuticals from 2020.
Dr. Homcy also founded Relay Therapeutics, Inc., Marea Therapeutics, Inc., and Maze Therapeutics, Inc., where he is working as Chairman from 2019.
Dr. Homcy also currently works at BridgeBio Pharma LLC, as Lead Director & Chairman-Chairman from 2020, CytomX Therapeutics Holdings LLC, as Director from 2012, Ambys Medicines, Inc., as Director, Population Health Investment Co., Inc., as Independent Director, The Johns Hopkins University, as Trustee, and Third Rock Ventures LLC, as Partner from 2010 to 2022.
Dr. Homcy also formerly worked at Cephalon, Inc., as Director in 2011, COR Therapeutics, Inc., as Director, Executive VP-Research & Development from 1998 to 2002, Millennium Pharmaceuticals, Inc., as Director from 2002 to 2008, Geron Corp., as Director, Kosan Biosciences, Inc., as Director from 2003 to 2008, Cytokinetics, Inc., as Director in 2008, MyoKardia, Inc., as Non-Employee Class II Director from 2013 to 2017, Topica Pharmaceuticals, Inc., as Director, Pliant Therapeutics, Inc., as Independent Director from 2015 to 2022, Wyeth Holdings LLC, as President-Medical Research, The Trustees of Columbia University in The City of New York, as Professor in 1995, The General Hospital Corp., as Principal in 1990, The University of California, San Francisco, as Professor, Lederle Laboratories, as President-Medical Research Division from 1990 to 1994, Harvard Medical School, as Associate Professor in 1990, Presbyterian Hospital, Inc., as Clinical Professor in 1995, and UCSF School of Medicine, as Clinical Professor.
Dr. Homcy received his undergraduate degree and doctorate degree from The Johns Hopkins University.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
BRIDGEBIO PHARMA, INC. 0,66%	21/06/2024	1 230 085 ( 0,66% )	31 M $	30/06/2024

Postes actifs de Charles Homcy

Sociétés	Poste	Début
BRIDGEBIO PHARMA, INC.	Fondateur	01/01/2015
POPULATION HEALTH INVESTMENT CO., INC.	Directeur/Membre du Conseil	-
BridgeBio Pharma LLC	Directeur/Membre du Conseil	01/11/2018
Maze Therapeutics, Inc.	Fondateur	-
Ambys Medicines, Inc.	Directeur/Membre du Conseil	-
The Johns Hopkins University	Directeur/Membre du Conseil	-
Third Rock Ventures LLC	Consultant / Advisor	01/01/2010
CytomX Therapeutics Holdings LLC	Directeur/Membre du Conseil	06/10/2010

Anciens postes connus de Charles Homcy

Sociétés	Poste	Fin
PLIANT THERAPEUTICS, INC.	Directeur/Membre du Conseil	16/06/2022
░░░░░░ ░░░░░ ░░░░░░░░░░░░░ ░░░░	░░░░░░░░░	░░░░░░░░░░
░░░░░░░░░░ ░░░░	░░░░░░░░░ ░░░░░░░░░	░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░ ░░░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	░░░░░░░░░░
░░░░░░░░░░░░░ ░░░░░░░░░░░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	░░░░░░░░░░

Formation de Charles Homcy

The Johns Hopkins University

Doctorate Degree